WORLDWIDE ORPHAN DRUG
SALES IN 2022: TOP 20
Celgene to be Number One in
Orphan Drug Sales in 2022 with
BMS and Novartis in Second and
Third Place. AZ, Abbvie and J&J
Set to March up the Orphan Sales
It is expected that Celgene will
overtake Novartis as the world’s
number one orphan drug company in 2022, climbing two places,
and pushing Novartis down to
One product contributes the
majority of orphan sales for two of
the top four; Celgene (Revlimid,
80% of sales ) and BMS (Opdivo,
68% of sales).
Seven of the Top 10 companies
by orphan drug sales in 2022 are
forecast to be Global Majors.
The Top 5 companies in 2022 are
forecast to account for almost one
third ( 30.6%) of the orphan drug
2022: TOP 20 SELLING
ORPHAN DRUGS IN THE
Revlimid (lenalidomide) will be
the No.1 Orphan Drug in 2022.
EvaluatePharma® finds that Revlimid will be the world’s largest
orphan drug in 2022, with sales of
$13.6B for all indications. Revlimid from Celgene was first approved in December 2005 for the
orphan treatment of myelodysplas-tic syndrome. Revlimid is also approved for the orphan indications
Non-Hodgkin’s lymphoma and
multiple myeloma and remains in
development for a number of other
Orphan drug chart 4
Orphan drug chart 5
Note: Sales represent company reported sales where available, otherwise
based on an average of equity analyst estimates. USA sales represent sales
for all indications.
EvaluatePharma® analysed the Top 10 selling USA drugs which treated
fewer than 10,000 patients in 2016.
*Revenues per patient: An estimate of the dollar ($) revenues per year received, by a company, per patient for a drug in the USA market. This takes
into account the cost per patient (average mg per year multiplied by the cost
per mg), off-invoice discount and patient compliance. Prices for products
in the US are sourced from Medicare Part B, NADAC, FSS and Medicaid.
Availability of a price point determines choice of source. The source is kept
consistent across years to reflect a clear trend in pricing.